http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101730868-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-005 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 |
| filingDate | 2013-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2017-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101730868-B1 |
| titleOfInvention | Pharmaceutical composition comprising VSIG4 inhibitor for preventing or treating ovarian cancer |
| abstract | The present invention relates to a pharmaceutical composition for preventing or treating ovarian cancer, which comprises VSIG4 protein expression or activity inhibitor, particularly VSIG4 blocking antibody, as an active ingredient, wherein VSIG4 is expressed in tumor associated macrophage (TAM) And is associated with the suppression of tumor-specific T-cell function, such as reducing T-cell proliferation and production of IFN-g. In addition, since blocking antibody against VSIG4 was prepared and T cell function of TAM was blocked by inhibiting the function of T-cell mediated by VSIG4, it was expected that it could be utilized as a therapeutic agent for ovarian cancer do. |
| priorityDate | 2013-09-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 99.